// App-Quantinova.ai

192 : Upadacitinib versus Adalimumab on Routine Assessment of Patient Index Data 3 (RAPID3) in Patients with Psoriatic Arthritis

Researchers

Presenter

  • Laura Coates

Principal Investigators

  • Arthur Kavanaugh

  • Erin McDearmon-Blondell

  • Arthur Mandelin

  • Tianming Gao

  • William Tillett

Medical Centers

  • Rheumatology, Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom

  • Nuffield Department of Orthopaedics, Rheumatology, and Musculoskeletal Sciences,, Oxford University Hospitals NHS Trust, Oxford, UK, Oxford, United Kingdom

  • University of California, San Diego, La Jolla, CA

  • Northwestern University, Feinberg School of Medicine, Chicago, IL

Locations

  • United Kingdom

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Musculoskeletal

  • Dermatology

Disease

  • Psoriatic arthritis

Biomarkers

  • Plasminogen Activator, Urokinase

  • Malondialdehyde

Drug/Treatment

  • ABT-494

  • Adalimumab

Outcome

  • N/A

Study Design

  • Placebo Control

  • Double Blind/Blinded

Phase

  • N/A

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved